Stanley Watowich
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$1.3MFederal grants as PI4 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
4 awards · $1.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 30, 2018 | NIH | STTR Phase I Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration | $358K | RIDGELINE THERAPEUTICS LLC with UNIVERSITY OF TEXAS MED BR GALVESTON |
| Sep 18, 2018 | NIH | STTR Phase I Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration | $358K | RIDGELINE THERAPEUTICS LLC |
| Sep 1, 2018 | NIH | STTR Phase I Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes | $300K | RIDGELINE THERAPEUTICS LLC with UNIVERSITY OF TEXAS MED BR GALVESTON |
| Aug 21, 2018 | NIH | STTR Phase I Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes | $300K | RIDGELINE THERAPEUTICS LLC |
Peer ranks
Federal funding#1,514
Awards as PI#566
Patents#273
Companies
- RIDGELINE THERAPEUTICS LLCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.